Cells from animals
|
|
|
|
Anti-inflammation |
RAW264.7 cells |
Downregulate IL-1α, IL-1β, IL-2, IL-10, MCP-1, COX-2, MMP-1, SOCS3 induced by LPS and suppress LPS-induced the phosphorylation of STAT3 |
[18] |
RAW264.7 cells |
Suppress NF-κB and MAPK signaling in LPS-stimulated |
[124] |
VSMCs |
Suppress inflammation response via inactivating NF-κB and suppressing proinflammatory gene expression |
[78] |
DCs |
Inhibit DC maturation via upregulation of Dabs and downregulate the Src/PI3K/Akt-NF-κB-inflammatory pathways |
[111] |
RAW264.7 cells |
Attenuate secretion of TNF-α or MCP-1 |
[125] |
|
Endothelium protection |
RAW264.7 cells |
Ameliorate overproduction of ROS induced by oxLDL |
[18] |
MPMs |
Inhibit ROS formation and block the vital step in activation of NADPH oxidase-membrane translocation of p47phox |
[16] |
RAW264.7 cells |
Protected sialic acid against H2O2-induced degradation |
[125] |
|
Lipid lowering |
RAW264.7 cells |
Ameliorate lipid deposition |
[18] |
Raw 264.7 cells |
Improve the protein expression of ABCG1 and ABCA1 to promote cholesterol efflux |
[125] |
Raw 264.7 cells |
Upregulate the protein expression of ABCA1, ABCG1, and LXRα and downregulate the protein expression of PCSK9, P53, P21, and P16 |
[126] |
|
Antiapoptosis |
NRK cells |
Activate autophagy |
[127] |
RAW264.7 cells |
Promote autophagy by increasing expression of LC3-II/I and Beclin1 and block the expression of MST1 induced by ox LDL |
[86] |
RAW264.7 cells |
Activate the PI3K/AKT pathway |
[78] |
EPCs |
Activate ERK and the ERK signaling pathway |
[113] |
|
Cells from human
|
|
|
|
Anti-inflammation |
HUVECs |
Attenuate caveolin-1 expression in endothelial cells |
[128] |
HUVECs |
Reduce intracellular ROS and inhibit of NF-κB and AP-1 activation |
[129] |
HUVECs |
Downregulate mRNA expression of MCP-1 and alleviate nuclear translocation of NF-κB p65 subunit through attenuating the TLR-NF-κB signaling pathway |
[32] |
PBMCs |
Suppress cytokine and TNF-α release by modulating TLR-NF-κB signaling pathway and TLR-mediated MAPK pathway |
[77] |
HUVECs |
Inhibit expression of proinflammatory factors and endothelin-1 |
[130] |
VSMCs |
Inhibit TNFα-mediated vascular inflammatory responses |
[131] |
HUVECs |
Inhibitory effect on MCP-1 as well as inflammatory cytokines including IL-1β, IL-6, and TNF-α
|
[132] |
|
Anti-apoptosis |
HaVSMCs |
Decrease relative expression levels of members of the mitochondrial apoptotic pathway, including P53, puma and Noxa, caspase-3, and caspase-8 |
[133] |
EA.hy926 cells |
Regulate Akt/GSK3β signaling pathway by increasing the expression of p-Akt and p-GSK3β
|
[134] |
|
Lowering lipid |
Human HepG2 cell line |
Promote selective uptake of HDL-C by enhancing SR-BI expression through stimulating the PPAR γ/LXRα pathway. |
[61] |
THP-1 macrophages |
Increase ABCA1 expression and cholesterol efflux through LXRα pathway to promote RCT |
[62] |